Ainos enters VELDONA license deal with partner-funded development, secures $600,000 upfront fee
AIMD•Ainos entered a VELDONA license deal under which its pharmaceutical development partner will fund development for the first two globally licensed indications. The agreement includes a $600,000 initial license fee and 25% of applicable net sublicensing revenue; Ainos also cited a potential $10 million framework.
1. License deal terms
The agreement shifts clinical and regulatory execution to the licensee, which will fund development for the first two globally licensed indications: Sjögren's disease and thrombocytopenia. Ainos said the $600,000 initial license fee is payable within 15 business days once payment conditions are met, and it will receive 25% of applicable net sublicensing revenue; the company also cited a potential $10 million framework tied to the initial fee, additional indication licenses and a first-sublicense fee.
